Agios Pharmaceuticals (AGIO) Receivables - Other (2013 - 2026)

Agios Pharmaceuticals (AGIO) has 14 years of Receivables - Other data on file, last reported at $4.1 million in Q2 2026.

• Quarterly Receivables - Other fell 17.69% year-over-year to $4.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $4.1 million (down 17.69% YoY) and the FY2024 annual result came in at $4.1 million, up 46.23% from the prior year.
• Receivables - Other slipped to $4.1 million in Q2 2026, from $16.1 million in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $16.1 million in Q1 2026 to a low of $1.2 million in Q3 2023.
• A 5-year average of $4.1 million and a median of $3.5 million in 2024 frame the typical range for Receivables - Other.
• Annual changes were most pronounced in 2022 — Receivables - Other jumped 430.76% — and 2023, when it sank 68.84%.
• Tracing AGIO's Receivables - Other over 5 years: stood at $2.2 million in 2022, then increased by 27.38% to $2.8 million in 2023, then jumped by 46.23% to $4.1 million in 2024, then increased by 22.39% to $5.0 million in 2025, then slipped by 18.39% to $4.1 million in 2026.
• The last three Receivables - Other figures came in at $4.1 million (Q2 2026), $16.1 million (Q1 2026), and $5.0 million (Q3 2025), per Business Quant data.